Regulation of Chemerin Bioactivity by Plasma Carboxypeptidase N, Carboxypeptidase B (Activated Thrombin-activable Fibrinolysis Inhibitor), and Platelets*

Xiao-Yan Du†, Brian A. Zabel†, Timothy Mylès‡, Samantha J. Allen§, Tracy M. Handel*‡, Peter P. Lee‡, Eugene C. Butcher†,‡, and Lawrence L. Leung†,‡,

From the †Division of Hematology and the ‡Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, the §Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, and the ‡†Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92039

Chemerin is a potent chemoattractant for cells expressing the serpinoid receptor CMKLR1 (chemokine-like receptor 1), such as plasmacytoid dendritic cells and tissue macrophages. The bioactivity of chemerin is post-translationally regulated; the attractant circulates in blood in a relatively inactive form (prochemerin) and is activated by carboxyl-terminal proteolytic cleavage. We discovered that plasma carboxypeptidase N (CPN) and B (CPB or activated thrombin-activable fibrinolysis inhibitor, TAFIa) enhanced the bioactivity of 10-mer chemerin peptide NH₃-YFPGQAFSK-COOH by removing the carboxyl-terminal lysine (K). Sequential cleavages of either a prochemerin peptide (NH₃-YFPGQAFSKALPRS-COOH) or recombinant full-length prochemerin by plasmin and CPN/CPB substantially increased their chemotactic activities. Endogenous CPN present in circulating plasma enhanced the activity of plasmin-cleaved prochemerin. In addition, we discovered that platelets store chemerin protein and release it upon stimulation. Thus circulating CPN/CPB and platelets may potentially contribute to regulating the bioactivity of leukocyte chemoattractant chemerin, and further extend the molecular link between blood coagulation/fibrinolysis and CMKLR1-mediated immune responses.

* This work was supported, in whole or in part, by National Institutes of Health Grants R01 HL75350 (to L. L.) and AI56205, AI057229, and DK56339 (to E. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† Present address: Maxygen Inc., 515 Galveston Dr., Redwood City, CA 94063.
‡ To whom corresponding should be addressed: VA Palo Alto Health Care System, 3801 Miranda Ave. (11), Palo Alto, CA 94304. Fax: 650-736-0974; E-mail: lawrence.leung@stanford.edu.

The abbreviations used are: CMKLR1, chemokine-like receptor 1; CPN, carboxypeptidase N; CPB, carboxypeptidase B; TAFI, thrombin-activable fibrinolysis inhibitor; MGTA, DL-2-mercaptomethyl-3 guanidinoethylthio-ketone; HPLC, high performance liquid chromatography; PRP, platelet-rich plasma; PIPES, piperazine-N,N′-bis(2-ethanesulfonic acid); RT, reverse transcription; ELISA, enzyme-linked immunosorbent assay; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; PPP, platelet-poor plasma.
about 50 nM and is activated by thrombin in complex with thrombomodulin on the vascular endothelial surface. CPB inhibits fibrin degradation by removing carboxyl-terminal lysines from partially digested fibrin, which prevents further incorporation of fibrinolytic plasminogen and tissue plasminogen activator (12, 13). CPB is thermolabile and has a half-life of ~15 min at 37 °C (14). We have shown that CPB also has broad substrate reactivity and is able to cleave and inactivate bradykinin, C3a, C5a, and thrombin-cleaved osteopontin (15–17). CPN and CPB may play complementary roles, with the former being constitutively active and capable of regulating systemic anaphylatoxins, and the latter activated locally at sites of vascular injury to provide site-specific anti-inflammatory control. Peptidases can also modulate the biological activity of certain chemokines (4). For example, dipetidyl peptidase (DPP-IV/CD26), a serine protease, inactivates CXCL9, CXCL10, CXCL11, and CXCL12 by cleaving these chemokines in the amino terminus (18, 19).

Platelets store a variety of potent cytokines and chemokines within α-granules that are released upon cell activation. Platelet degranulation products, particularly the leukocyte chemotactic proteins, which include CXCL4 (platelet factor 4), β-thromboglobulin, CLC5 (RANTES), CCL7 (monocyte chemotactic protein 3), and CXCL12 (stromal-derived factor 1), may contribute to host defense and also play a role in pathophysiological conditions (20, 21). For example, platelet factor 4 forms complexes with heparin in blood or some glycosaminoglycans on platelet surfaces to form the major antigen implicated in heparin-induced thrombocytopenia (22, 23). Platelets not only store CXCL12 but also express its receptor CXCR4, a coreceptor for cellular entry of human immunodeficiency virus, type 1, suggesting that platelets may be involved in host defense (24).

In this study, we found that plasma CPN or CPB can function in concert with plasmin to elicit and augment the chemotactic activity of prochemerin. Furthermore, we show that platelets could store and release partially active chemerin upon activation. Thus circulating CPN/CPB and platelets may contribute to regulating the bioactivity of leukocyte chemotactic chemerin and further extend the molecular link between blood coagulation/fibrinolysis and CMKLR1-mediated immune responses.

**EXPERIMENTAL PROCEDURES**

**Materials**—Recombinant human chemerin21–157, polyclonal goat anti-human chemerin antibodies, and biotinylated polyclonal goat anti-human antibodies were from R & D Systems (Minneapolis, MN). Peptides 9-mer, YFPQQAFKS (chemerin149–157); 10-mer, YFPQQAFSDK (chemerin149–158); and 15-mer, YFPQQAFSKALPRS (chemerin149–163) were synthesized by Eli Lilly (Hayward, CA). Heparin, dithiotheren 2-mercaptoethanol-3 guanidinoethylthiopropanoic acid (MGTA) was obtained from Calbiochem (La Jolla, CA). Collagen and ADP were from Chrono-log (Havertown, PA). Human plasma-derived CPB (TAFIA) and a CPB activity kit were from American Diagnostica (Stamford, CT). Thrombin receptor-activating peptide (SFLLRN peptide), d-phenylalanyl-1-prolyl-1-arginine chloromethyl ketone (PPACK), heparin-agarose, and bovine serum albumin were from Sigma. Human soluble thrombomodulin and recombinant CPN were kind gifts from Drs. John Moser and Mariko Nagashima (Berlex Biosciences, Richmond, CA). Hep3B and MEG-01 cells were from the American Type Culture Collection.

**Preparation of Recombinant Prochemerin**—Recombinant prochemerin was purified as previously published (8). Briefly, prochemerin with a carboxyl-terminal His6 tag was cloned into a pACP67 (BD Biosciences) and transfected into Sf-9 cells. The mature prochemerin protein has the amino acid sequence NH2-ADPELTEAQ-FAFSKALPRS (chemerin 149–157); 10-mer, YFPGQFAFSK (chemerin 149–158); and 15-mer, YFPGQFAFSKALPRS (chemerin 149–163) were synthesized by Eli Lilly (Hayward, CA). Hep3B and MEG-01 cells were from the American Type Culture Collection.

**Preparation of Recombinant Prochemerin**—Recombinant prochemerin was purified as previously published (8). Briefly, prochemerin with a carboxyl-terminal His6 tag was cloned into a pACP67 (BD Biosciences) and transfected into Sf-9 cells. The mature prochemerin protein has the amino acid sequence NH2-ADPELTEAQ-FAFSKALPRS (chemerin 149–157); 10-mer, YFPGQFAFSK (chemerin 149–158); and 15-mer, YFPGQFAFSKALPRS (chemerin 149–163) were synthesized by Eli Lilly (Hayward, CA). Hep3B and MEG-01 cells were from the American Type Culture Collection.

**Preparation of Recombinant Prochemerin**—Recombinant prochemerin was purified as previously published (8). Briefly, prochemerin with a carboxyl-terminal His6 tag was cloned into a pACP67 (BD Biosciences) and transfected into Sf-9 cells. The mature prochemerin protein has the amino acid sequence NH2-ADPELTEAQ-FAFSKALPRS (chemerin 149–157); 10-mer, YFPGQFAFSK (chemerin 149–158); and 15-mer, YFPGQFAFSKALPRS (chemerin 149–163) were synthesized by Eli Lilly (Hayward, CA). Hep3B and MEG-01 cells were from the American Type Culture Collection.

**Preparation of Recombinant Prochemerin**—Recombinant prochemerin was purified as previously published (8). Briefly, prochemerin with a carboxyl-terminal His6 tag was cloned into a pACP67 (BD Biosciences) and transfected into Sf-9 cells. The mature prochemerin protein has the amino acid sequence NH2-ADPELTEAQ-FAFSKALPRS (chemerin 149–157); 10-mer, YFPGQFAFSK (chemerin 149–158); and 15-mer, YFPGQFAFSKALPRS (chemerin 149–163) were synthesized by Eli Lilly (Hayward, CA). Hep3B and MEG-01 cells were from the American Type Culture Collection.

**Preparation of Recombinant Prochemerin**—Recombinant prochemerin was purified as previously published (8). Briefly, prochemerin with a carboxyl-terminal His6 tag was cloned into a pACP67 (BD Biosciences) and transfected into Sf-9 cells. The mature prochemerin protein has the amino acid sequence NH2-ADPELTEAQ-FAFSKALPRS (chemerin 149–157); 10-mer, YFPGQFAFSK (chemerin 149–158); and 15-mer, YFPGQFAFSKALPRS (chemerin 149–163) were synthesized by Eli Lilly (Hayward, CA). Hep3B and MEG-01 cells were from the American Type Culture Collection.

**Preparation of Recombinant Prochemerin**—Recombinant prochemerin was purified as previously published (8). Briefly, prochemerin with a carboxyl-terminal His6 tag was cloned into a pACP67 (BD Biosciences) and transfected into Sf-9 cells. The mature prochemerin protein has the amino acid sequence NH2-ADPELTEAQ-FAFSKALPRS (chemerin 149–157); 10-mer, YFPGQFAFSK (chemerin 149–158); and 15-mer, YFPGQFAFSKALPRS (chemerin 149–163) were synthesized by Eli Lilly (Hayward, CA). Hep3B and MEG-01 cells were from the American Type Culture Collection.
CPB, 50 μl of 10-mer (1 μM) was treated with either CPN or CPB (30 nM) for 30 min at 37 °C, and the reaction mixtures were loaded onto a Waters C18 (4.6 × 150 mm) column and separated with a 0–35% acetonitrile gradient in 0.1% trifluoroacetic acid (v/v) by HPLC. For 15-mer cleavage, 15-mer (1 μM) was incubated with plasmin (1 μM) at 37° for 30 min; the reaction was then terminated by PPACK (serine protease inhibitor) (10 μM). CPN or CPB (30 nM) was added and incubated for 30 min at 37 °C. 40 μl of each reaction mixture (15-mer, 15-mer plus plasmin, 15-mer plus plasmin and CPN/CPB) was analyzed by reverse phase HPLC as described above.

Kinetic Analysis of Hydrolysis of 10-mer Chemerin Peptides by CPB and CPN—Michaelis-Menten kinetics was used to determine the $K_m$ and $k_{cat}$ for the hydrolysis of 10-mer peptide (YFPGQFAFSK) by CPB and CPN. The concentrations of 10-mer peptides ranged from 20 to 320 μM and were digested with 50 nM CPB or 5 nM CPN for 5 min at 37 °C in assay buffer. The reactions were stopped by boiling for 5 min. Cleaved peptide was resolved by HPLC, and the nmol of peptide generated was determined from the peak area of cleaved peptide. The values for $K_m$ and $k_{cat}$ were determined by plotting the initial velocities of cleavage against the different substrate concentrations and then fitting to the Michaelis-Menten equation by nonlinear regression analysis as previously described (15). The experiments were performed in duplicate, and the data were pooled for analysis.

CPB Activity Assays—100 μl of CPN (10 nM) and CPB (15 nM) were added to a 96-well plate in the presence or absence of MGTA at the indicated concentrations. 50 μl of chromogenic CPB (TAFIa) substrate was used in each well as described in the Actichrome CPB kit. Activated CPB (TAFIa) ranging from 0.125 to 2 μg/ml was used to construct the standard curve. All of the tests were performed in duplicate. The plate was placed in an ELISA plate reader at 37 °C with constant mixing, and the absorbance at 420 nm was read 30 min after sample addition.

Development of Sandwich ELISA for Chemerin—Polyclonal goat anti-human chemerin antibodies were used to coat 96-well plates at a concentration of 4 μg/ml. Biotinylated polyclonal goat anti-human chemerin antibodies (0.2 μg/ml) and horse-radish peroxidase-labeled streptavidin was used to detect bound chemerin protein. The lower limit of detection of chemerin in this assay was ~0.5 ng/ml. For the determination of chemerin levels in plasma, the samples were diluted 10-fold before assay.

Mass Spectrometry—MALDI-TOF mass spectrometry was performed by the Stanford Protein and Nucleic Acid Core Facility.

Statistical Analyses—The data are expressed as the means ± S.D., and statistical evaluation was performed using Student’s $t$ test. Differences were considered to be significant when $p < 0.05$ (*) or 0.005 (**).

RESULTS

CPN and CPB Up-regulate Chemerin 10-mer Activity by Removing the Carboxyl-terminal Lysine Residue—The synthetic 9-mer chemerin peptide YFPGQFAFS (chemerin149–157) induced substantial, dose-dependent migration of human CMKLR1/L1.2 transfectants (Fig. 1A) with a peak response occurring at 10–100 nM. Empty vector transfected controls did not migrate to the 9-mer (data not shown). The 10-mer peptide YFPGQFAFSK (chemerin149–158) did not induce any significant CMKLR1-dependent chemotaxis even at 10 μM concen-
CPN, CPB, and Platelets Regulate Chemerin Activity

**TABLE 1**

Hydrolysis of chemerin 10-mer peptides by CPB and CPN

| Substrate Enzyme       | K_m  | k_cat | k_cat/K_m |
|------------------------|------|-------|-----------|
| Chemerin               | CPB  | 122.8 | 6.4       | 2.7 ± 0.1   | 2.2 × 10^6|
| Bradykinin             | CPB  | 70.6  | 4.8       | 19.7 ± 0.4  | 2.8 × 10^6|
| C5α6-74                | CPB  | 219.0 | 16.2      | 29.5 ± 0.7  | 1.3 × 10^7|
| C3α6-77                | CPB  | 35.9  | 6.6       | 8.4 ± 0.6   | 2.3 × 10^5|
| FBα-Arg96–104          | CPB  | 361.4 | 69.2      | 1.5 ± 0.1   | 4.2 × 10^5|
| FBβ-Lys96–104          | CPB  | 14.3  | 0.7       | 13.6 ± 0.2  | 9.5 × 10^6|
| FBγ-Lys54–62           | CPB  | 34.0  | 4.1       | 2.6 ± 0.1   | 7.6 × 10^4|
| FBγ-Lys77–85           | CPB  | 238.9 | 5.2       | 5.9 ± 0.3   | 2.5 × 10^4|
| Chemerin               | CPN  | 170.6 | 27.2      | 80.3 ± 5.0  | 4.7 × 10^7|
| Bradykinin             | CPN  | 302.7 | 29.1      | 9.1 ± 0.2   | 3.0 × 10^4|
| C5α6-74                | CPN  | 602.2 | 74.3      | 9.3 ± 0.4   | 1.5 × 10^4|
| C3α                    | CPN  | 77.1  | 11.2      | 57.9 ± 2.1  | 7.5 × 10^5|
| FBα-Arg96–104          | CPN  | 448.9 | 43.8      | 2.9 ± 0.1   | 6.5 × 10^6|
| FBβ-Lys96–104          | CPN  | 53.2  | 4.9       | 10.9 ± 1.3  | 2.6 × 10^4|
| FBγ-Lys54–62           | CPN  | 657.6 | 20.5      | 3.5 ± 0.1   | 5.3 × 10^3|
| FBγ-Lys77–85           | CPN  | 3727.0| 408.6     | 11.8 ± 0.8  | 3.2 × 10^7|

We analyzed the mixtures of 10-mer treated with either CPN or CPB by HPLC and found that the 10-mer/CPN mixture had a major peak with a retention time of 28.25 min, which is almost identical to that of the purified 9-mer (28.26 min), and different from the 10-mer (25.90 min). For the 10-mer treated with CPB, we detected two major fractions corresponding to the 10-mer (25.90 min) and 9-mer (28.28 min) (Fig. 1C). The efficiency of 10-mer cleavage by CPB at 30 nM was about 60%, likely because CPB is thermolabile under the experimental conditions used. In this work, CPN was also used at 30 nM to compare with CPB enzymatic activity. Of note, the plasma levels of proCPB and CPN are ~50 and 100 nM, respectively (11, 14).

**Determination of the Kinetic Parameters for the Hydrolysis of 10-mer Peptide (Chemerin149–158) by CPB and CPN** —The hydrolysis of chemerin149–158 by CPB gave estimates for K_m (122.8 ± 6.4 μM), k_cat (2.7 ± 0.1 s⁻¹), and k_cat/K_m (2.2 × 10⁶ M⁻¹ s⁻¹) (Table 1). The concentrations of chemerin149–158 ranged from 20 to 320 μM, and chemerin was digested with 50 nM CPB. The k_cat/K_m for chemerin cleavage was about 10-fold less efficient compared with bradykinin and C5α6-74, C3α6-77 but comparable with fibrinopeptide γ-Lys77–85. Meanwhile, the k_cat/K_m of 10-mer cleavage by CPB is 4.7 × 10⁻⁵ M⁻¹ s⁻¹, which is about 20-fold faster than CPB, and is about 20-fold faster than bradykinin and C5α peptide but similar to that of C3α peptide.

**Sequential Proteolysis of Prochemerin 15-mer Peptide by Plasmin and Carboxypeptidases Synergistically Enhances Bioactivity** —The synthetic chemerin 15-mer peptide, YFPGQFAFSKALPRS (chemerin149–163) is chemotactically inert (Fig. 2A). Treatment of the 15-mer with CPN or CPB alone had no effect on chemerin bioactivity. However, sequential treatment of the 15-mer with plasmin and CPN or CPB dramatically enhanced its chemotactic activity. The proteolytic products were evaluated by HPLC to determine processing sites. Plasmin first cleaved the 15-mer (retention time, 29.96 min) to 10-mer (retention time: 25.3 min; the peak with the retention time at 12.4 min is the carboxyl-terminal plasmin-generated 5-mer). CPN or CPB then converted the 10-mer to the 9-mer (retention time, ~27.6 min) (Fig. 2B).

**Sequential Proteolysis of Prochemerin by Plasmin and Carboxypeptidases Synergistically Enhances Bioactivity** —We next asked whether sequential treatment of chemotactically inert concentrations of prochemerin by plasmin and CPN or CPB could activate the attractant and generate the NH₂-YFPGQ-FAFS-COOH form. Plasmin alone cleaved prochemerin and increased its chemotactic bioactivity (Fig. 3A). Sequential treatment of prochemerin with plasmin and CPN or CPB, however, dramatically enhanced its chemotactic activity (Fig. 3B). The proteolytic products were evaluated by mass spectrometry to determine the processing sites (Fig. 3C). Plasmin first cleaved prochemerin (17730.12 Da) to the NH₂-YFPGQFAFSK-COOH form (16301.13 Da), and then CPN or CPB removed the terminal lysine to generate a desLys form (16156.36 Da) with enhanced activity. Prochemerin treated with CPN and CPB alone did not induce CMKL1-mediated chemotaxis (data not shown).

**Endogenous Plasma CPN Is Critical for the Increased Activity of Plasmin-cleaved Prochemerin** —Prochemerin was incubated with plasmin and then treated with PPACK to inhibit serine protease activity. Plasmin-treated prochemerin was added to normal platelet-poor plasma (PPP) as well as PPP treated with...
MGTA, a specific inhibitor for CPN but not CPB (Fig. 4A). Plasmin-cleaved prochemerin did not induce CMKLR1-mediated chemotaxis (Fig. 4B). Incubation with PPP, however, dramatically increased its bioactivity, which was inhibited by MGTA, indicating that endogenous plasma CPN is critical for activating low concentrations of plasmin-cleaved chemerin (Fig. 4B).

**Identification of Chemerin in Platelet**—Platelets store various coagulation proteins as well as inflammatory factors. To determine whether platelets are also involved in chemerin expression, Western blot analysis and RT-PCR were performed. Chemerin was detected by Western blot in total platelet lysates, with a molecular mass of ~110 kDa, similar to recombinant chemerin21–157 (Fig. 5A). Although platelets are anuclear, long lived mRNAs are present in the cytosol, including messages for certain chemokines (26). We detected chemerin mRNA in platelets by RT-PCR. An expected 229-bp PCR product was amplified from cDNAs of platelets, as well as from Hep3B (hepatocellular carcinoma cell line) and MEG-01 (megakaryotic cell line) cells (Fig. 5B). Identity of the amplified chemerin PCR product was confirmed by direct sequencing.

**Platelets Release Chemerin upon Activation**—As quantified by ELISA, the concentration of chemerin in PRP was 48 ± 1.1 ng/ml. The addition of thrombin (5 units/ml) to PRP increased the chemerin level to 78 ± 0.7 ng/ml (p < 0.005) (Fig. 6A). The addition of thrombin to PPP, on the other hand, had no effect on chemerin activities (Fig. 6B). Thrombin itself did not induce the chemotaxis of CMKLR1-transfected cells, and thrombin does not cleave and activate prochemerin (8). Thus we conclude that the increased chemerin bioactivity in thrombin-treated PRP was not due to proteolysis of circulating plasma prochemerin by thrombin but rather was dependent on the release of chemerin from platelets following thrombin activation. Furthermore, platelet-activating agonists such as thrombin receptor-activating peptide, collagen, and, to a lesser extent, ADP induced the release of chemerin from washed platelets (Fig. 6C), which corresponded with an increase in chemerin bioactivity as determined by CMKLR1 transfectant migration (Fig. 6D).

We next investigated whether the chemerin released from activated platelets is a prochemerin form or an active isoform.
The same amount of prochemerin and active chemerin\textsuperscript{21–157} were used as controls for platelet-derived chemerin (as quantified by ELISA) in transwell assays using CMKLR1/L1.2 transfectants. Chemerin activity released from activated platelets is higher than prochemerin but substantially less active than chemerin\textsuperscript{21–157} (Fig. 7A). The specific response of platelet-derived chemerin to CMKLR1 transfectants was confirmed in the chemotaxis assay using nontransfected cells as controls (Fig. 7B). This suggested that platelets might release chemerin in a partially active form, or platelet-derived chemerin is a mixture of different forms of chemerin, which probably could undergo further proteolysis to fully express its biological activities. With the addition of plasmin/CPB or plasmin/CPN to platelet releasates, no enhanced chemerin activities were observed, which is likely due to the presence of various plasmin inhibitors, including α\textsubscript{2}-antiplasmin, which is known to be released from activated platelets (27) (data not shown). When platelet-derived chemerins were partially purified by heparin-agarose chromatography as previously described (8), a significantly increased chemerin activity was detected after adding plasmin, plasmin/CPB, and plasmin/CPN (Fig. 7C). Interestingly, chemerin activity was also enhanced even in the presence of CPN or CPB alone (Fig. 7C), indicating that at least a portion of the chemerins released from activated platelets has been already cleaved to a form that is accessible to CPN or CPB cleavage.

**DISCUSSION**

In this study, we report that plasma-derived CPN and CPB substantially up-regulated the bioactivity of plasmin-cleaved prochemerin via the removal of the carboxyl-terminal lysine residue, adding a novel mechanism to prochemerin processing and activation by proteases (Table 2). We demonstrated this in three different in vitro scenarios: 1) CPN and CPB removed the carboxyl-terminal lysine from a 10-mer chemerin peptide and converted it to a bioactive 9-mer; 2) plasmin cleaved prochemerin 15-mer to 10-mer, which was subsequently converted to the bioactive 9-mer by CPN or CPB; and 3) sequential proteolysis of recombinant prochemerin protein by plasmin followed by CPN or CPB generated a chemerin isoform with

**FIGURE 5. Platelets contain chemerin mRNA and protein.** A, Western blot analysis of chemerin in platelet lysates. B, RT-PCR analysis of chemerin message in various cell lines and platelets.

**FIGURE 6. Platelets release chemerin upon activation.** A, ELISA quantification of total chemerin present in resting and thrombin (5 units/ml) activated PRP. B, in vitro transwell chemotaxis of CMKLR1/L1.2 cells to PRP, and PRP/thrombin (5 units/ml), PPP, and PPP/thrombin (5 units/ml). Thrombin at 5 units/ml was added to PRP or PPP at 37 °C for 5 min. C and D, Identification of chemerin in washed platelet lysates by Western blot analysis (C) or in vitro transwell chemotaxis of CMKLR1/L1.2 cells (D). The platelets were treated with the indicated platelet-activating agonists at 37 °C for 3 min: thrombin receptor-activating peptide (20 μM), thrombin (5 units/ml), collagen (10 μg/ml), and ADP (10 μM). 200 μl of platelet releasates were tested in chemotaxis assays. The results represent one of three independent experiments and are expressed as the means ± S.D. (n = 3). **, p < 0.005.
potent chemoattractant activity (carboxyl-terminal sequence NH$_2$-YFPGQFAFS-COOH). These data show that CPN and CPB generate a highly active “desLys” form of plasmin-cleaved chemerin. Interestingly, we also found that platelets can regulate chemerin bioactivity by storing and releasing it upon stimulation. We have therefore identified additional circulating factors (Table 2) that contribute to the regulation of chemerin bioactivity and further link the processes of blood coagulation/fibrinolysis with mediators that regulate leukocyte migration.

There is a growing appreciation for the role of extracellular matrix metalloproteinases and serine proteases such as DPP-IV/CD26 and cathepsin G in regulating the activity of chemokines at the post-translational level (1). These enzymes are particularly adept at modifying chemokines to dampen immune responses. For example, CCL7 is a physiological substrate of matrix metalloproteinase 2; matrix metalloproteinase 2-cleaved CCL7 acts as a general chemokine antagonist by binding to but not activating the CC-chemokine receptors-1, -2, and -3, thereby blocking leukocyte recruitment and dampening inflammation (28). Carboxypeptidases CPN and CPB are well known for their ability to inactivate a number of pro-inflammatory mediators including C5a, C3a, bradykinin, and thrombin-cleaved osteopontin (15–17). In the case of plasmin-cleaved prochemerin, CPN/CPB enhances, rather than diminishes, the chemotactic activity of the attractant under the current experimental conditions.

Cells that are chemerin-responsive include plasmacytoid dendritic cells and macrophages, leukocytes capable of functioning as “immune interpreters”; in the absence of “danger signals,” chemerin-recruited plasmacytoid dendritic cell and macrophages may play an immune suppressive role, dampening inflammation through interleukin-10 and transforming growth factor $\beta$ secretion and regulating T cell responses. Thus CPN/CPB may serve to dampen inflammatory responses by inactivating anaphylatoxins and by recruiting immune suppressive CMKLR1-positive leukocytes to sites of sterile tissue injury.

The regulation of chemerin bioactivity at a site of tissue injury in vivo appears to involve a complex interplay among many enzymatic components. In our study, plasmin at 1 $\mu$M efficiently cleaves prochemerin in vitro. Although this is a substantial concentration of plasmin, human platelets have well defined plasminogen binding sites, and these binding sites are further increased by 5-fold upon platelet activation (29, 30). In addition, it has been reported that thrombin stimulation specifically induces plasminogen activation that is mediated by endogenous urokinase-type plasminogen activator (31). Thus given the substantial plasma concentration of plasminogen ($\approx 2.2$ $\mu$M), it is entirely plausible that prochemerin, upon release from activated platelets, will be efficiently cleaved to chemerin by plasmin generated locally at the site of vascular inflammation in vivo. Plasmin-cleaved prochemerin can be further activated by CPB and CPN. CPB is activated locally by endothelial cell bound thrombin/thrombomodulin and enhances the chemotactic activity of plasmin-cleaved

![FIGURE 7. Bioactivity of platelet-derived chemerin. A, comparison of chemotactic activity of chemerin released from activated platelets, prochemerin, and the active form chemerin$^{21–157}$. B, the specific chemotactic response of platelet-derived chemerin to CMKLR1/L1.2 transfectants. C, proteolytic regulation of platelet-derived chemerin bioactivity. Platelet-derived chemerin was partially purified by heparin affinity chromatography (8). Fractions containing chemerin were eluted with 0.6 M of NaCl. The concentration of chemerin was quantitated by ELISA. The conditions of platelet-derived chemerin treated with CPN, CPB, plasmin, plasmin/CPN, or plasmin/CPB were identical to that in Fig. 3. The results represent one of three independent experiments and are expressed as the means ± S.D. (n = 3). *, $p < 0.05$; **, $p < 0.005$.](image)

### TABLE 2

Prochemerin cleavages by various proteases

| Protease | C-terminal sequence | Amino acid order |
|----------|---------------------|------------------|
| Unprocessed | YFPGQFAFSKALPRS | 21–163 |
| Plasmin/CPB | YFPGQFAFS | 21–157 |
| Plasmin/CPN | YFPGQFAFS | 21–157 |
| Plasmin | YFPGQFAFSK | 21–158 |
| Elastase | YFPGQFAFS | 21–157 |
| Tryptase | YFPGQFAFSK | 21–158 |
| Cathepsin G | YFPGQFA | 21–155 |
| Staphopain B | YFPGQFAFS | 21–157 |
| FVIIa | ND |
| FXIIa | ND |

CPN, CPB, and Platelets Regulate Chemerin Activity

JANUARY 9, 2009 • VOLUME 284 • NUMBER 2

JOURNAL OF BIOLOGICAL CHEMISTRY

757
prochemerin via removal of the carboxyl-terminal lysine. At the same time, CPB, in its role as a fibrinolysis inhibitor, blocks plasmin generation, which would diminish the initial activation of circulating prochemerin. Thus CPB may limit the extent of prochemerin activation but enhance the activity of the plasmin-cleaved chemerin that has already been formed. Our study provides further evidence that CPB functions not only as an inhibitor of fibrinolysis, but also as a mediator of inflammatory responses. CPB may be important for local and specific action at sites of tissue damage, whereas constitutively active CPN may regulate its targets systemically.

Platelets are critical in maintaining normal hemostasis (32, 33). Activated platelets release granular proteins that include platelet agonists, adhesive proteins, and chemoattractants at the site of vascular injury, which may play a role in tissue inflammation and remodeling (34–36). In our study, we found that platelets store chemerin. Upon activation, platelets release a mixture of chemerin isoforms with different levels of bioactivity. Some of them would undergo further proteolysis to fully express its biological activity. Our future work will investigate the role of chemerin in platelet biology and tissue remodeling.

REFERENCES
1. Zabel, B. A., Zuniga, L., Ohyama, T., Allen, S. J., Cichy, J., Handel, T. M., and Butcher, E. C. (2006) Exp. Hematol. 34, 1106–1114.
2. Zabel, B. A., Silverio, A. M., and Butcher, E. C. (2005) J. Immunol. 174, 244–251.
3. Wittamer, V., Franssen, I. D., Vulcano, M., Mirjolet, J. F., Le Poul, E., Migeotte, I., Brézillon, S., Tyldesley, R., Blanpain, C., Dethex, M., Mantovani, A., Sozzani, S., Vassart, G., Parmentier, M., and Communi, D. (2001) J. Exp. Med. 198, 977–985.
4. Zabel, B. A., Ohyama, T., Zuniga, L., Kim, J. Y., Johnston, B., Allen, S. J., Guido, D. G., Handel, T. M., and Butcher, E. C. (2006) Exp. Hematol. 34, 1021–1032.
5. Parolini, S., Santoro, A., Marcenaro, E., Luini, W., Massardi, L., Facchetti, F., Communi, D., Parmentier, M., Majorana, A., Sironi, M., Tabellini, G., Moretta, A., and Sozzani, S. (2007) Blood 109, 3625–3632.
6. Zhang, Z., and Wang, F. S. (2005) Cell Mol. Immunol. 2, 411–417.
7. Wittamer, V., Bondue, B., Guillabert, A., Vassart, G., Parmentier, M., and Communi, D. (2005) J. Immunol. 175, 487–493.
8. Zabel, B. A., Allen, S. J., Kulig, P., Allen, J. A., Cichy, J., Handel, T. M., and Butcher, E. C. (2005) J. Biol. Chem. 280, 34661–34666.
9. Kulig, P., Zabel, B. A., Dubin, G., Allen, S. J., Ohyama, T., Potempa, J., Handel, T. M., Butcher, E. C., and Cichy, J. (2007) J. Immunol. 178, 3713–3720.
10. Wittamer, V., Grégoire, F., Robberecht, P., Vassart, G., Communi, D., and Parmentier, M. (2004) J. Biol. Chem. 279, 9956–9962.
11. Matthews, K. W., Mueller-Ortiz, S. L., and Wetsel, R. A. (2004) Mol. Immunol. 40, 785–793.
12. Redlitz, A., Tan, A. K., Eaton, D. L., and Plow, E. F. (1995) J. Clin. Invest. 96, 2534–2538.
13. Bajzar, L., Morser, J., and Neschim, M. (1996) J. Biol. Chem. 271, 16603–16608.
14. Ceresa, E., Van de Borne, K., Peeters, M., Lijnen, H. R., Declerck, P. J., and Gils, A. (2006) J. Biol. Chem. 281, 15878–15883.
15. Myles, T., Nishimura, T., Yun, T. H., and Leung, L. L. K. (2003) J. Biol. Chem. 278, 51059–51067.
16. Nishimura, T., Myles, T., Piliponsky, A. M., Kao, P. N., Berry, G. J., and Leung, L. L. K. (2007) Blood 109, 1992–1997.
17. Myles, T., and Leung, L. L. (2008) J. Biol. Chem. 283, 17789–17796.
18. Hildebrandt, M., and Schabath, R. (2008) Front. Biosci. 13, 1774–1779.
19. Gonzalez-Gronow, M., Kaczowka, S., Gawld, G., and Pizzo, S. V. (2008) Front. Biosci. 13, 1610–1618.
20. Boehlen, F., and Clemetson, K. J. (2001) Transfus. Med. 11, 403–417.
21. Brandt, E., Ludwig, A., Petersen, F., and Flad, H. D. (2000) Immunol. Rev. 177, 204–216.
22. Warke, T. E., Chong, B. H., and Greinacher, A. (1998) Thromb. Haemostasis 79, 1–7.
23. Cines, D. B., Rauova, L., Arpelly, G., Reilly, M. P., McKenzie, S. E., Sachais, B. S., and Poncz, M. (2007) J. Clin. Apher. 22, 31–36.
24. Clemetson, K. J., Clemetson, J. M., Proudfoot, A. E., Power, C. A., Baggiozini, M., and Wells, T. N. (2000) Blood 96, 4046–4054.
25. Du, X. Y., Clemetson, J. M., Navdaev, A., Magnenat, E. M., Wells, T. N., and Clemetson, K. J. (2002) J. Biol. Chem. 277, 35124–35132.
26. Power, C. A., Clemetson, J. M., Clemetson, J. K., and Wells, T. N. (1995) Cytokine 7, 479–482.
27. Plow, E. F., and Collen, D. (1988) Blood 85, 1069–1074.
28. McKibben, G. A., Gong, J. H., Tam, E. M., McCulloch, C. A., Clark-Lewis, I., and Overall, C. M. (2006) Science 298, 1202–1206.
29. Miles, L. A., and Plow, E. F. (1985) J. Biol. Chem. 260, 4303–4311.
30. Miles, L. A., Ginsberg, M. H., White, J. G., and Plow, E. F. (1986) J. Clin. Invest. 77, 2001–2009.
31. Lenich, C., Liu, J. N., and Gurewich, V. (1997) Blood 90, 3579–3586.
32. Andrews, R. K., and Berndt, M. C. (2004) Thromb. Res. 114, 447–453.
33. Clemetson, K. J., and Clemetson, J. M. (2007) Curr. Pharm. Des. 13, 2673–2683.
34. Du, X. Y., Sim, D. S., Lee, W. H., and Zhang, Y. (2006) Blood Cells Mol. Dis. 36, 414–421.
35. von Hundelshausen, P., Petersen, F., and Brandt, E. (2007) Thromb. Haemostasis 97, 704–713.
36. Stellos, K., and Gaw, M. (2007) Thromb. Haemostasis 98, 922–929.